86097-55-4

Upstream product

• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 93863-41-3 methyl (E)-7-(2,4-dichlorophenyl)-5-hydroxy-3-oxo-6-heptenoate 
• 70017-27-5 3-(2,4-Dichlorophenyl)propenal 
• 129752-85-8 (2S,4S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-2-methoxy-3,4-dihydro-2H-pyran-4-ol 
• 6752-48-3 (2S,4aS,6R,8R,8aR)-6-Methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-ol 
• 129752-76-7 (3aR,6R,7aR)-6-Methoxy-4-methylene-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one 
• 93863-43-5 methyl (E)-7-(2,4-dichlorophenyl)-3,5-dihydroxy-6-heptenoate 
• 874-42-0 2,4-dichlorobenzaldeyhde 

Downstream Products

• 111505-88-5 6-<2-(2,4-dichlorophenyl)ethyl>-5,6-dihydro-2H-pyran-2-one 
• 111506-05-9 Z,E-7-(2,4-dichlorophenyl)-2,4-heptadienoic acid 
• 111506-01-5 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-thiophen-3-yl-tetrahydro-pyran-2-one 
• 111505-91-0 (4S,6R)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-phenyl-tetrahydro-pyran-2-one 
• 111505-91-0 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-phenyl-tetrahydro-pyran-2-one 
• 111505-96-5 C₂₁H₁₈Cl₂F₃NO₄ 
• 111505-93-2 4-{(2S,4S)-2-[2-(2,4-Dichloro-phenyl)-ethyl]-6-oxo-tetrahydro-pyran-4-yl}-benzoic acid methyl ester 
• 111505-92-1 (4S,6S)-4-Biphenyl-4-yl-6-[2-(2,4-dichloro-phenyl)-ethyl]-tetrahydro-pyran-2-one 
• 111505-99-8 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(2-methoxy-phenyl)-tetrahydro-pyran-2-one 
• 111505-98-7 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(2-hydroxymethyl-phenyl)-tetrahydro-pyran-2-one 
• 111505-94-3 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(4-methoxy-phenyl)-tetrahydro-pyran-2-one 
• 111505-97-6 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(3-methoxy-phenyl)-tetrahydro-pyran-2-one 
• 111506-00-4 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(3-iodo-pyrazol-1-yl)-tetrahydro-pyran-2-one 
• 111505-95-4 (4S,6S)-6-[2-(2,4-Dichloro-phenyl)-ethyl]-4-(4-hydroxy-phenyl)-tetrahydro-pyran-2-one 

Relevant academic research and scientific papers

A new strategy for the synthesis of mevinic acid analogues

The reaction of the allylic carbonate 2 with organocopper derivatives is the key step of a new strategy for the synthesis of mevinic acid analogues. (Chemical Equation Presented).

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives

A series of 5-substituted 3,5-dihydroxypentanoic acids and their derivatives have been prepared and tested for inhibition of HMG-CoA reductase in vitro. In general, unless a carboxylate anion can be formed and the hydroxy groups remain unsubstituted in an erythro relationship, inhibitory activity is greatly reduced. Furthermore, only one enantiomer of the ring-opened form of lactone 6a(±) possesses the activity displayed by the racemate. Insertion of a bridging unit other than ethyl or (E)-ethenyl between the 5-carbinol moiety and an appropriate lipophilic moiety (e.g., 2,4-dichlorophenyl) attenuates activity.

PROCESS FOR PREPARING INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE VIA A CHIRAL SYNTHON

Totally synthetic analogs of the known inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, compactin and mevinolin, are prepared from a chiral synthon derived from D-glucose which has the same chirality as the natural products.